Search Results for "hATTR"

Alnylam is committed to providing the healthcare community with balanced, accurate, and high-quality information about our science, therapeutic areas, and products.

More than one search term is recommended to yield the most relevant results. By searching, you confirm that your query is unsolicited.

For more information about our FDA-approved therapies, please see the Full Prescribing Information:

Patisiran: Use in Patients with hATTR Amyloidosis with Cardiomyopathy and Polyneuropathy

Standard response letter on the use of patisiran in patients with hATTR and mixed phenotype from the APOLLO-B study.

Effect of Patisiran on Polyneuropathy and Cardiomyopathy in Patients with Hereditary Transthyretin Mediated (hATTR) Amyloidosis with a V122I or T60A Variant: A Phase 4 Observational Study

Pharmacokinetics and Pharmacodynamics of Patisiran in Patients with hATTR Amyloidosis and with Polyneuropathy After Liver Transplantation

For further information regarding your request, please connect with us by reaching out to your local Medical Science Liaison or contacting our Medical Information team.